for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Anavex Life Sciences Corp

AVXL.O

Latest Trade

14.39USD

Change

0.67(+4.88%)

Volume

1,147,030

Today's Range

13.43

 - 

14.46

52 Week Range

5.56

 - 

31.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.72
Open
13.63
Volume
1,147,030
3M AVG Volume
18.66
Today's High
14.46
Today's Low
13.43
52 Week High
31.50
52 Week Low
5.56
Shares Out (MIL)
76.02
Market Cap (MIL)
1,093.90
Forward P/E
-28.68
Dividend (Yield %)
--

Next Event

Q1 2022 Anavex Life Sciences Corp Earnings Release

Latest Developments

More

Anavex Life Sciences Reports Fiscal 2021 Year End Financial Results

Anavex Life Sciences Reports Data Review For Phase 2B/3 Trial Of Anavex2-73 In Patients With Alzheimer's Disease

Anavex Life Sciences Announces Publication Of Foundational Data For ANAVEX2-73 In Fragile X Syndrome (Autism)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Anavex Life Sciences Corp

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.

Industry

Business Services

Contact Info

51 W 52nd St Fl 7th

NEW YORK, NY

10019-6163

United States

+1.800.6893939

https://www.anavex.com

Executive Leadership

Christopher U. Missling

Chairman of the Board, President, Chief Executive Officer, Company Secretary

Sandra Boenisch

Principal Financial Officer, Treasurer

Adebayo Laniyonu

Senior Vice President - Nonclinical Development

Walter E. Kaufmann

Chief Scientific Officer

Edward R. Hammond

Chief Medical Officer

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (USD)

2019

-0.540

2020

-0.450

2021

-0.540

2022(E)

-0.502
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.58
Return on Equity (TTM)
-38.65

Latest News

Latest News

BRIEF-Anavex Life Sciences Announces First Participant Enrolled In Phase 1 Study Of Anavex 3-71

* ANAVEX LIFE SCIENCES ANNOUNCES FIRST PARTICIPANT ENROLLED IN PHASE 1 STUDY OF ANAVEX®3-71 (AF710B) Source text for Eikon: Further company coverage:

BRIEF-Anavex Life Says Co & Lincoln Park Capital Fund Entered Into First Amendment To Purchase Agreement

* ANAVEX LIFE SCIENCES - ON JULY 1, CO & LINCOLN PARK CAPITAL FUND, LLC ENTERED INTO FIRST AMENDMENT TO PURCHASE AGREEMENT

BRIEF-Anavex Life Sciences Announces Exceeding Of Enrollment Target For Anavex2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

* ANAVEX LIFE SCIENCES ANNOUNCES EXCEEDING OF ENROLLMENT TARGET FOR THE ANAVEX®2-73 (BLARCAMESINE) U.S. PHASE 2 RETT SYNDROME CLINICAL TRIAL

BRIEF-Anavex Life Sciences Announces Initiation Of First-In-Human Phase 1 Study Of Anavex®3-71

* ANAVEX LIFE SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN PHASE 1 STUDY OF ANAVEX®3-71 (AF710B) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Anavex Life Sciences Q2 Loss Per Share $0.12

* ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Anavex Life Sciences Corp Files Prospectus Supplement Related To Issuance, Sale Of Up To $30.3 Million In Common Shares To Lincoln Park Capital Fund, Llc

* ANAVEX LIFE SCIENCES CORP FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE, SALE OF UP TO $30.3 MILLION IN COMMON SHARES TO LINCOLN PARK CAPITAL FUND, LLC Source text for Eikon: [ID: https://bit.ly/3bV33mP] Further company coverage:

BRIEF-Anavex Life Sciences Corp - May Offer And Sell Shares Of Common Stock Having Offering Price Of Up To $50 Million From Time To Time

* ANAVEX LIFE SCIENCES CORP - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $50 MILLION FROM TIME TO TIME - SEC FILING Source text for Eikon: [ID: https://bit.ly/2WkFZY2] Further company coverage:

BRIEF-Anavex Life Sciences Announces Publication Of Foundational Data For Anavex®2-73 In Multiple Sclerosis

* ANAVEX LIFE SCIENCES ANNOUNCES PUBLICATION OF FOUNDATIONAL DATA FOR ANAVEX®2-73 (BLARCAMESINE) IN MULTIPLE SCLEROSIS (MS)

BRIEF-BBI Life Sciences Refers To Announcement By Co & LJ Future For Proposed Privatisation

* BBI LIFE SCIENCES CORP REFERS TO ANNOUNCEMENT BY CO & LJ FUTURE, AS OFFEROR, FOR PROPOSED PRIVATISATION OF CO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up